Apeloa Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 522 million yuan, a decrease of 7.22% compared with the same period last year. The company's total operating revenue was 4.823 billion yuan, down 11.41% year-on-year; net cash inflow from operating activities was 74.3295 million yuan, down 81.75% year-on-year. The latest gross margin was 29.55%, an increase of 3.82 percentage points over the same period last year, achieving two consecutive years of growth; the latest return on equity was 7.95%, a decrease of 0.39 percentage points from the same period last year. The company's diluted earnings per share was 0.45 yuan, down 7.12% year-on-year.
Apeloa Pharmaceutical Co LtdNet profit fell 7.22% year-on-year, revenue down 11.41%, and operating cash flow dropped 81.75%.